Key result
CRISPR/dCas9 upregulates APOA1 and PON1 for 46 days, reducing oxidative and inflammatory stress in vitro.
Why the study?
APOA1 and PON1 are key HDL proteins, and an in vitro model for their endogenous longstanding upregulation was needed to decipher their protective mechanisms.
CRISPR/dCas9-mediated upregulation of APOA1 and PON1 in human hepatocytes provides a functional in vitro model for studying their protective antioxidant and anti-inflammatory effects.
This hepatocyte model enables mechanistic studies of APOA1/PON1; leaves open clinical translation to HDL therapies.
Apolipoprotein A1 (APOA1) and paraoxonase 1 (PON1) are key proteins of high-density lipoproteins (HDL). The aim of the present study was to obtain and characterize an in vitro model for endogenous APOA1 and PON1 longstanding upregulation in hepatocytes that can be further used to decipher the mechanisms of their protective action. Cultured human hepatocytes (HuH-7 cell line) were transfected with CRISPR/dCas9 activation plasmids targeting APOA1/PON1 genes. Following selection with specific antibiotics, RNA sequencing was used for the transcriptomic characterization of the transfected hepatocytes. The functionality of the secreted APOA1/PON1 was evaluated as the capacity of the conditioned medium (CM) from transfected HuH-7 to modulate the oxidative and inflammatory stress in TNFα-activated primary human umbilical endothelial cells (HUVEC). The results showed that: (1) a robust, longstanding upregulation (46 days) of endogenous APOA1/PON1 was obtained after CRISPR/dCas9 transfection and antibiotics selection; (2) APOA1/PON1 upregulation led to a modified transcriptomic profile and increased the expression of several antioxidant genes in transfected hepatocytes as demonstrated by RNAseq analysis; (3) secreted APOA1/PON1 were functional as demonstrated by the CM ability to reduce the levels of reactive oxygen species and inflammatory markers (VCAM-1, MCP-1) in TNFα-activated HUVEC. In conclusion, we achieved an experimental model of successful longstanding upregulation of endogenous APOA1 and PON1 in human hepatocytes. The targeted proteins are secreted in a functional form and can be used for deciphering their complex mechanism of protective action in various pathological conditions.
No takes yet. Share an insight, caveat, or question.
Haratau et al. (2026) studied this question. CRISPR/dCas9 activation plasmids targeting APOA1/PON1 genes was evaluated on Upregulation of endogenous APOA1/PON1 and functionality of secreted proteins. CRISPR/dCas9 transfection in human hepatocytes achieved a longstanding upregulation (46 days) of functional endogenous APOA1 and PON1 that reduced oxidative and inflammatory stress in HUVEC cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: